Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
53
HEAL Quote, Financials, Valuation and Earnings
Last price:
$30.13
Seasonality move
:
-1.64%
Day range:
$29.66 - $29.80
52-week range:
$24.48 - $35.73
Dividend yield:
0.08%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.9K
Avg. volume:
9.5K
1-year change:
1.26%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HEAL
Global X HealthTech ETF
|
$29.77 | -- | -- | -- | $0.02 | 0.08% | -- |
|
AGNG
Global X Aging Population ETF
|
$36.23 | -- | -- | -- | $0.14 | 0.8% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$47.10 | -- | -- | -- | $0.03 | 0.07% | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
$32.23 | -- | -- | -- | $0.32 | 0.99% | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$26.46 | -- | -- | -- | $0.16 | 1.17% | -- |
|
PPH
VanEck Pharmaceutical ETF
|
$102.17 | -- | -- | -- | $0.39 | 1.89% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HEAL
Global X HealthTech ETF
|
-- | 1.781 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.484 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 1.886 | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | 1.095 | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 0.936 | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | 0.233 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- | -- |
Global X HealthTech ETF vs. Competitors
-
Which has Higher Returns HEAL or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Global X HealthTech ETF's net margin of --. Global X HealthTech ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HEALGlobal X HealthTech ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About HEAL or AGNG?
Global X HealthTech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X HealthTech ETF has higher upside potential than Global X Aging Population ETF, analysts believe Global X HealthTech ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings HEALGlobal X HealthTech ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is HEAL or AGNG More Risky?
Global X HealthTech ETF has a beta of 1.219, which suggesting that the stock is 21.903% more volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.722%.
-
Which is a Better Dividend Stock HEAL or AGNG?
Global X HealthTech ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.08%. Global X Aging Population ETF offers a yield of 0.8% to investors and pays a quarterly dividend of $0.14 per share. Global X HealthTech ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEAL or AGNG?
Global X HealthTech ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Global X HealthTech ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Global X HealthTech ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X HealthTech ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEALGlobal X HealthTech ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns HEAL or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to Global X HealthTech ETF's net margin of --. Global X HealthTech ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HEALGlobal X HealthTech ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About HEAL or GNOM?
Global X HealthTech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X HealthTech ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe Global X HealthTech ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HEALGlobal X HealthTech ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is HEAL or GNOM More Risky?
Global X HealthTech ETF has a beta of 1.219, which suggesting that the stock is 21.903% more volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.286, suggesting its more volatile than the S&P 500 by 28.563%.
-
Which is a Better Dividend Stock HEAL or GNOM?
Global X HealthTech ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.08%. Global X Genomics & Biotechnology ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. Global X HealthTech ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEAL or GNOM?
Global X HealthTech ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. Global X HealthTech ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, Global X HealthTech ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X HealthTech ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEALGlobal X HealthTech ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns HEAL or IBRN?
iShares Neuroscience and Healthcare ETF has a net margin of -- compared to Global X HealthTech ETF's net margin of --. Global X HealthTech ETF's return on equity of -- beat iShares Neuroscience and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HEALGlobal X HealthTech ETF-- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- -
What do Analysts Say About HEAL or IBRN?
Global X HealthTech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Neuroscience and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X HealthTech ETF has higher upside potential than iShares Neuroscience and Healthcare ETF, analysts believe Global X HealthTech ETF is more attractive than iShares Neuroscience and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings HEALGlobal X HealthTech ETF0 0 0 IBRNiShares Neuroscience and Healthcare ETF0 0 0 -
Is HEAL or IBRN More Risky?
Global X HealthTech ETF has a beta of 1.219, which suggesting that the stock is 21.903% more volatile than S&P 500. In comparison iShares Neuroscience and Healthcare ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HEAL or IBRN?
Global X HealthTech ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.08%. iShares Neuroscience and Healthcare ETF offers a yield of 0.99% to investors and pays a quarterly dividend of $0.32 per share. Global X HealthTech ETF pays -- of its earnings as a dividend. iShares Neuroscience and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEAL or IBRN?
Global X HealthTech ETF quarterly revenues are --, which are smaller than iShares Neuroscience and Healthcare ETF quarterly revenues of --. Global X HealthTech ETF's net income of -- is lower than iShares Neuroscience and Healthcare ETF's net income of --. Notably, Global X HealthTech ETF's price-to-earnings ratio is -- while iShares Neuroscience and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X HealthTech ETF is -- versus -- for iShares Neuroscience and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEALGlobal X HealthTech ETF-- -- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- --
-
Which has Higher Returns HEAL or IDNA?
iShares Genomics Immunology and Healthcare ETF has a net margin of -- compared to Global X HealthTech ETF's net margin of --. Global X HealthTech ETF's return on equity of -- beat iShares Genomics Immunology and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HEALGlobal X HealthTech ETF-- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -
What do Analysts Say About HEAL or IDNA?
Global X HealthTech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Genomics Immunology and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X HealthTech ETF has higher upside potential than iShares Genomics Immunology and Healthcare ETF, analysts believe Global X HealthTech ETF is more attractive than iShares Genomics Immunology and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings HEALGlobal X HealthTech ETF0 0 0 IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 -
Is HEAL or IDNA More Risky?
Global X HealthTech ETF has a beta of 1.219, which suggesting that the stock is 21.903% more volatile than S&P 500. In comparison iShares Genomics Immunology and Healthcare ETF has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.579%.
-
Which is a Better Dividend Stock HEAL or IDNA?
Global X HealthTech ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.08%. iShares Genomics Immunology and Healthcare ETF offers a yield of 1.17% to investors and pays a quarterly dividend of $0.16 per share. Global X HealthTech ETF pays -- of its earnings as a dividend. iShares Genomics Immunology and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEAL or IDNA?
Global X HealthTech ETF quarterly revenues are --, which are smaller than iShares Genomics Immunology and Healthcare ETF quarterly revenues of --. Global X HealthTech ETF's net income of -- is lower than iShares Genomics Immunology and Healthcare ETF's net income of --. Notably, Global X HealthTech ETF's price-to-earnings ratio is -- while iShares Genomics Immunology and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X HealthTech ETF is -- versus -- for iShares Genomics Immunology and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEALGlobal X HealthTech ETF-- -- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- --
-
Which has Higher Returns HEAL or PPH?
VanEck Pharmaceutical ETF has a net margin of -- compared to Global X HealthTech ETF's net margin of --. Global X HealthTech ETF's return on equity of -- beat VanEck Pharmaceutical ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HEALGlobal X HealthTech ETF-- -- -- PPHVanEck Pharmaceutical ETF-- -- -- -
What do Analysts Say About HEAL or PPH?
Global X HealthTech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Pharmaceutical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X HealthTech ETF has higher upside potential than VanEck Pharmaceutical ETF, analysts believe Global X HealthTech ETF is more attractive than VanEck Pharmaceutical ETF.
Company Buy Ratings Hold Ratings Sell Ratings HEALGlobal X HealthTech ETF0 0 0 PPHVanEck Pharmaceutical ETF0 0 0 -
Is HEAL or PPH More Risky?
Global X HealthTech ETF has a beta of 1.219, which suggesting that the stock is 21.903% more volatile than S&P 500. In comparison VanEck Pharmaceutical ETF has a beta of 0.549, suggesting its less volatile than the S&P 500 by 45.102%.
-
Which is a Better Dividend Stock HEAL or PPH?
Global X HealthTech ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.08%. VanEck Pharmaceutical ETF offers a yield of 1.89% to investors and pays a quarterly dividend of $0.39 per share. Global X HealthTech ETF pays -- of its earnings as a dividend. VanEck Pharmaceutical ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEAL or PPH?
Global X HealthTech ETF quarterly revenues are --, which are smaller than VanEck Pharmaceutical ETF quarterly revenues of --. Global X HealthTech ETF's net income of -- is lower than VanEck Pharmaceutical ETF's net income of --. Notably, Global X HealthTech ETF's price-to-earnings ratio is -- while VanEck Pharmaceutical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X HealthTech ETF is -- versus -- for VanEck Pharmaceutical ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEALGlobal X HealthTech ETF-- -- -- -- PPHVanEck Pharmaceutical ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
